Luminary Award

The PMWC Luminary Award is honoring a figure whose leadership has significantly contributed over the years to the advancement and one of the many aspects of patient-centric healthcare, therefore shaping what is known today as precision medicine.

Award Recipients: Silicon Valley

Jennifer Doudna

2017

Pioneered the Groundbreaking Crispr-Cas9 Genome Editing Technology

Edward F. Chang

2017

Pioneer in Human Brain Circuit Mapping to Advance Precision Neuropathology

Roger Perlmutter

2016

Expedited Development of Groundbreaking Therapies

Laura Esserman

2016

Breast Cancer Treatment Paradigm Shifter

Ron Davis

2015

Developed R-loop Technique of Electron Microscopy

Jay Flatley

2014

Established Illumina as the leader in sequence technology

Janet Woodcock

2013

FDA Director, fast-tracked targeted drugs through FDA approval

Brian Druker

2012

Co-inventor, blockbuster drug, Gleevec

George Church

2011

Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”

Lee Hood

2010

Inventions included the automated DNA sequencer and a tool for synthesizing DNA

Pioneer Award

The PMWC Pioneer Award is given on occasion to a rare individual who presaged the present day excitement regarding personalized medicine, and, at a time when technology wasn’t as evolved and less peer encouragement existed, nevertheless, made substantial contributions to the field.

Award Recipients: Silicon Valley

Steve Quake

2017

Steve Quake has pioneered innovative approaches to biological measurement

James Allison

2017

Pioneered Cancer Immunotherapy Through Discovery of the Immune Checkpoint Blockade

Irv Weissman

2016

Pioneer in Regenerative Medicine & Cancer Stem Cells

Ralph Snyderman

2016

Widely recognized as “Father of Personalized Medicine”

Craig Venter

2015

1st Draft Human Gen., 1st Complete Diploid Human Gen., and 1st Synth. Bact. Cell

Dennis Lo

2015

Discovered That An Unborn Fetus Releases Fetal DNA Into Maternal Plasma

Yuet Wain Kan

2014

The first to establish that a single DNA mutation could lead to a human disease, and the first to diagnose a human disease by using DNA

Award Recipients: Israel

Michael Hayden

2014

Developer, First Predictive Test for Huntington’s Disease

Kim Popovits

2013

Launched both Earliest Genetically-Targeted Therapy and Molecular Diagnostic Assay

Award Recipients: UK

Jonathan K.C. Knowles

2015

Personalized Medicine Leader in both Academia and the Pharmaceutical Industry

Most Promising Company Award

The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.

Two Pore Guys

Two Pore Guys

Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system. Website: twoporeguys.com

Gritstone Oncology

Gritstone Oncology

Every patient’s tumor is molecularly unique – Gritstone Oncology deploys a proprietary tumor antigen prediction model based upon patient tumor sequencing/mass spectrometry to deliver antigens as personalized therapeutic vaccine alongside checkpoint inhibitors. Website: gritstoneoncology.com

healthmyne

HEALTHMYNE

HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports. Website: healthmyne.com

insilico

INSILICO MEDICINE

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Website: insilicomedicine.com

accel-diag

ACCEL DIAGNOSTICS

AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels. Website: acceldx.com

t2-biosystems

T2 BIOSYSTEMS

T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014. Website: t2biosystems.com

elminda

ELMINDA

ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks. Website: elminda.com

horizon

HORIZON DISCOVERY

Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014. Website: horizondiscovery.com

auxogyn

AUXOGYN

Auxogyn is dedicated to advancing women’s reproductive health through diagnostic technologies that generate information to be used by physicians and their patients in making treatment decisions. We pursue a regulatory path to assure our technologies are safe and effective and meet stringent regulatory standards. Received FDA Clearance, June 2014. Website: auxogyn.com

quanta-life

QUANTALIFE

QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011. Website: bio-rad.com

Applied-I1

APPLIED IMMUNE TECHNOLOGIES

Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016. Website: tcrl.co.il

BHL

BOSTON HEART LAB

Boston Heart Diagnostics is a heart health management company providing integrated diagnostic and patient management solutions that are advancing cardiovascular disease risk assessment, monitoring and treatment. The Company’s goal is to predict, prevent, manage and reverse cardiovascular disease by improving patient assessment and management. Acquired by Eurofins Scientific, December 2014. Website: bostonheartdiagnostics.com

Testimonials